Kidney transplantation is the most effective treatment for kidney failure, yet more than 25% of kidney transplants in Canada fail within 10 years due to rejection or other injuries. Currently, doctors monitor kidney health using a blood test that measures creatinine levels, but this method only detects problems once significant damage has already occurred, limiting opportunities for early intervention.

A newer blood test, known as donor-derived cell-free DNA (dd-cfDNA), has shown promise in detecting kidney injury much earlier, before creatinine levels become abnormal. Despite its benefits, this test is currently only available through specialized laboratories in the United States, making it costly and inaccessible for many Canadian patients.

This project aims to bring dd-cfDNA testing to British Columbia and Alberta, improving access to this advanced diagnostic tool. The project team will first work with local transplant laboratories to ensure that the test performs at the same high standard as U.S.-based labs. Once validated, the test will be formally introduced for clinical use in both provinces to support patient care.

To assess the impact of dd-cfDNA testing, the project will evaluate key measures such as the speed of test results, equitable access for patients and the test’s influence on treatment decisions. A comprehensive economic analysis will also be conducted to determine the most cost-effective way to implement the test in the healthcare system.

By collaborating with national leaders and patient partners, the project team will share findings and best practices with other transplant centres across Canada. This initiative aims to accelerate the adoption of dd-cfDNA testing nationwide, ultimately improving outcomes for kidney transplant patients by enabling earlier detection and intervention.